logo
Redefining the transistor: The ideal building block for artificial intelligence

Redefining the transistor: The ideal building block for artificial intelligence

SINGAPORE, March 28, 2025 /PRNewswire/ -- The team led by Associate Professor Mario Lanza from the Department of Materials Science and Engineering in the College of Design and Engineering at the National University of Singapore, has just revolutionised the field of neuromorphic computing by inventing a new super-efficient computing cell that can mimic the behaviour of both electronic neurons and synapses. The work, titled " Synaptic and neural behaviours in a standard silicon transistor" was published in the scientific journal Nature on 26 March 2025 and is already attracting interest from leading companies in the semiconductor field.
Electronic neurons and synapses are the two fundamental building blocks of next-generation artificial neural networks. Unlike traditional computers, these systems process and store data in the same place, eliminating the need to waste time and energy transferring data from memory to the processing unit (CPU). The problem is that implementing electronic neurons and synapses with traditional silicon transistors requires interconnecting multiple devices — specifically, at least 18 transistors per neuron and 6 per synapse. This makes them significantly larger and more expensive than a single transistor.
The team led by Professor Lanza has found an ingenious way to reproduce the electronic behaviours characteristic of neurons and synapses in a single conventional silicon transistor. The key lies in setting the resistance of the bulk terminal to a specific value to produce a physical phenomenon called 'impact ionisation,' which generates a current spike very similar to what happens when an electronic neuron is activated. Additionally, by setting the bulk resistance to other specific values, the transistor can store charge in the gate oxide, causing the resistance of the transistor to persist over time, mimicking the behaviour of an electronic synapse. Making the transistor operate as a neuron or synapse is as simple as selecting the appropriate resistance for the bulk terminal. The physical phenomenon of 'impact ionisation' had traditionally been considered a failure mechanism in silicon transistors, but Professor Lanza's team has managed to control it and turn it into a highly valuable application for the industry.
This discovery is revolutionary because it allows the size of electronic neurons to be reduced by a factor of 18 and that of synapses by a factor of 6. Considering that each artificial neural network contains millions of electronic neurons and synapses, this could represent a huge leap forward in computing systems capable of processing much more information while consuming far less energy. Furthermore, the team has designed a cell with two transistors — called Neuro-Synaptic Random Access Memory (NSRAM) — that allows switching between operating modes (neuron or synapse), offering great versatility in manufacturing since both functions can be reproduced using a single block, without the need to dope the silicon to achieve specific substrate resistance values.
The transistors used by Professor Lanza's team to implement these advanced neurons and synapses are not cutting-edge transistors like those manufactured in Taiwan or Korea, but rather traditional 180-nanometer node transistors, which can be produced by Singapore-based companies. According to Professor Lanza, 'once the operating mechanism is discovered, it's now more a matter of microelectronic design'.
The first author of the paper, Dr Sebastián Pazos, who is from King Abdullah University of Science and Technology, commented, 'Traditionally, the race for supremacy in semiconductors and artificial intelligence has been a matter of brute force, seeing who could manufacture smaller transistors and bear the production costs that come with it. Our work proposes a radically different approach based on exploiting a computing paradigm using highly efficient electronic neurons and synapses. This discovery is a way to democratise nanoelectronics and enable everyone to contribute to the development of advanced computing systems, even without access to cutting-edge transistor fabrication processes.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

123Invent Inventor Develops New Safety Feature for Vehicles
123Invent Inventor Develops New Safety Feature for Vehicles

Yahoo

time31 minutes ago

  • Yahoo

123Invent Inventor Develops New Safety Feature for Vehicles

PITTSBURGH, June 9, 2025 /PRNewswire/ -- "I wanted to create a safety feature for vehicles to reduce impact and injuries in the event of a vehicular accident," said an inventor, from Gerrardstown, W.V., "so I invented the SAFETY FEATURE. My design can be utilized with new or older vehicles to enhance safety." The patent-pending invention provides a new safety feature for vehicles. In doing so, it helps reduce impact to people in the event of an accident. As a result, it increases safety and peace of mind. It also could help minimize injuries. The invention features a unique design that is easy to install so it is ideal for vehicle owners, manufacturers, dealerships, etc. Additionally, it can be installed on both new and used vehicles. The modified design for used vehicles would help save time, money, and resources. The SAFETY FEATURE is currently available for licensing or sale to manufacturers or marketers. For more information, visit Or contact Jason Bare at 304- 279-9721 or email info@ View original content to download multimedia: SOURCE InventHelp

Florida Cancer Specialists & Research Institute Launches Liquid Biopsy
Florida Cancer Specialists & Research Institute Launches Liquid Biopsy

Yahoo

timean hour ago

  • Yahoo

Florida Cancer Specialists & Research Institute Launches Liquid Biopsy

Statewide Practice Continues to Enhance Genomic Testing to Advance Cancer Care, Improve Cure Rates and Enhance Patient Experience FORT MYERS, Fla., June 9, 2025 /PRNewswire/ -- Liquid biopsy, a blood test that swiftly detects signs of cancerous tumors and cells traveling in the bloodstream, is now available at Florida Cancer Specialists & Research Institute, LLC (FCS), offering significant benefits in the diagnosis and treatment of many of the most common cancers, particularly those in advanced stages. Liquid biopsy is used increasingly to assess lung, colorectal, breast and prostate cancer as well as cancers of the blood. "Liquid biopsy is especially effective for providing genetic information quickly for various types of advanced cancers to help physicians assess and better target treatments that may work best and monitor patient response," said Jennifer Gass, PhD, associate director of the FCS Genetics Laboratory. Biopsies are the definitive method for confirming the presence of cancer. Traditionally, samples of tissue, cells or fluid are taken from the body during a surgical procedure and then sent to a laboratory for analysis. Liquid biopsy utilizes a simple blood draw to draw samples of circulating tumor DNA (ctDNA) for testing. Dr. Gass notes, "Additionally, because it is minimally invasive and easy to repeat on an ongoing basis, liquid biopsy is significantly more comfortable for patients." This latest advancement reflects the continued expansion of the statewide practice's comprehensive genomic testing capabilities, which are enhancing diagnostic accuracy, guiding treatment decisions for physicians and improving clinical outcomes for cancer patients. Since launching next-generation sequencing (NGS) capabilities at its centralized in-house laboratory in 2021, FCS has expanded its menu of testing options available to the 250 physicians serving more than 102,000 patients, adding up to more than 4.2 million visits, annually across Florida. FCS recently surpassed more than 16,000 molecular tests processed at its state-of-the-art laboratory facility in Fort Myers. "It is rare for a community oncology practice to offer the comprehensive scope of genomic testing that we have available for our patients," said FCS President & Managing Physician Lucio N. Gordan, MD. "With genomic profiling, we are able to identify actionable mutations for the majority of cancer patients, creating a uniquely personalized treatment approach. It is at the core of our focus on precision oncology." Other recent additions to the NGS testing menu at FCS include HRD, or homologous recombination deficiency, which analyzes the DNA of a tumor and determines potential treatment response to PARP inhibitors, a class of drugs that target cancer cells; a small heme NGS panel that detects mutations associated with myeloproliferative neoplasms; and a quantitative assay that monitors BCR::ABL gene fusions after treatment in certain blood cancers. Dr. Gass noted, "Molecular technology continues to grow and provide better ways of visualizing an individual's unique genetic makeup. We are very excited to see how the technology evolves in the future." Nicole Radford, FACHE, MS, MT(ASCP), FCS vice president of laboratory services, emphasizes the value of critical partnerships the practice has established with global technology and software leaders to evolve and advance the critical infrastructure needed to optimize clinical decision making. FCS' recent acquisition of the Illumina NovaSeq, for example, allows the sequencing of many more samples more deeply with even faster turnaround times. ""Our turnaround times—consistently within the industry standard—match those of leading commercial laboratories. What truly sets us apart at FCS is our ability to incorporate each patient's clinical information into the analysis," Radford notes. "This allows us to deliver insights that go beyond the report, offering providers more meaningful, tailored information that drives better decisions and outcomes for our patients." Radford oversees a highly specialized team of clinical experts skilled in multiple disciplines. "Our clinical team has expanded tremendously and now includes three board-certified genetic scientists and several licensed genetic and molecular scientists," she said. "Testing is a laborious and highly detailed process that requires enormous discipline and adherence to multiple process steps and the highest quality standards, and that's not simple. Each team member complements the other and they continue to do a tremendous job to get the very best tests and results out as quickly as possible." Nathan H. Walcker, FCS chief executive officer, said, "The quality and success of these initiatives demonstrates our commitment to making the necessary investments to remain at the forefront of innovations and technologies that ensure the very best outcomes for every patient who entrusts their care to FCS." About Florida Cancer Specialists & Research Institute, LLC: ( For more than 40 years, Florida Cancer Specialists & Research Institute (FCS) has embraced innovation to deliver world-class care and drive the dramatic transformation of oncology care through its robust clinical research program. FCS provides patients with access to a wide range of clinical trials, positioning it as a leader in research among private oncology practices in Florida and across the country. In fact, before receiving FDA approval, the majority of new cancer drugs in the U.S. were first made available to patients through participation in clinical trials at FCS. Our outstanding team of highly trained and dedicated physicians is committed to delivering tailored treatment plans that make the best use of cutting-edge precision oncology advancements to enhance patient outcomes. View original content to download multimedia: SOURCE Florida Cancer Specialists & Research Institute Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

123Invent Inventor Develops Modified Design for a Bathtub
123Invent Inventor Develops Modified Design for a Bathtub

Yahoo

timean hour ago

  • Yahoo

123Invent Inventor Develops Modified Design for a Bathtub

PITTSBURGH, June 9, 2025 /PRNewswire/ -- "I wanted to create a modified bathtub that would make bathing safer and more comfortable, especially for the elderly and young children," said an inventor, from Austin, Texas, "so I invented the HIGH RISE TUB. My design would allow a person to enter and exit the tub with ease and minimal effort." The invention provides a modified design for a bathtub. In doing so, it allows the user to safely enter and exit the tub. As a result, it eliminates the need for assistance. It also reduces the risk of injuries. Additionally, the invention features a durable and user-friendly design that is easy to use so it is ideal for the elderly, individuals with limited mobility, children, etc. The HIGH RISE TUB is currently available for licensing or sale to manufacturers or marketers. For more information, visit Or contact Jeanette Hope at 512- 705-7883 or email info@ View original content to download multimedia: SOURCE InventHelp Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store